NASDAQ:BRBI

BR Biopharma (BRBI) Stock Price, News & Analysis

BR Biopharma logo
$7.40 -0.22 (-2.89%)
Closing price 11/20/2026 03:59 PM Eastern
Extended Trading
$7.42 +0.02 (+0.27%)
As of 11/20/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About BR Biopharma Stock (NASDAQ:BRBI)

Advanced

Key Stats

Today's Range
$6.85
▼
$8.29
50-Day Range
$6.80
▼
$15.36
52-Week Range
$6.80
▼
$16.61
Volume
28,765 shs
Average Volume
9,484 shs
Market Capitalization
$87.39 million
P/E Ratio
52.86
Dividend Yield
4.32%
Price Target
N/A
Consensus Rating
Reduce

Company Overview

Brii Biosciences Limited is a biotechnology company focused on developing treatments for infectious diseases and other conditions with significant unmet medical needs. Founded in 2017, the company has operated in the United States and China.

Its research has included investigational therapies for chronic hepatitis B and other viral diseases, as well as drug-resistant bacterial infections. The company’s development programs have included BRII-179, a therapeutic vaccine candidate for hepatitis B, and BRII-835, an investigational RNA-based therapy. These candidates are not described here as approved or marketed medicines.

AI Generated. May Contain Errors.

BR Biopharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
15th Percentile Overall Score

BRBI MarketRank™: 
0.772312016865 of 5 stars

BR Biopharma scored higher than 15% of companies evaluated by MarketBeat, and ranked 762nd out of 813 stocks in the finance sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    BR Biopharma has received a consensus rating of Reduce. The company's average rating score is 1.50, and is based on no strong buy ratings, no buy ratings, 1 hold rating, and 1 sell rating.

  • Amount of Analyst Coverage

    BR Biopharma has only been the subject of 2 research reports in the past 90 days.

  • Read more about BR Biopharma's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of BR Biopharma is 52.86, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.17.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of BR Biopharma is 52.86, which means that it is trading at a more expensive P/E ratio than the Finance sector average P/E ratio of about 19.44.

  • Price to Book Value per Share Ratio

    BR Biopharma has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    0.12% of the float of BR Biopharma has been sold short.
  • Short Interest Ratio / Days to Cover

    BR Biopharma has a short interest ratio ("days to cover") of 2.05, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in BR Biopharma has recently increased by 1,264.34%, indicating that investor sentiment is decreasing significantly.
  • Dividend Leadership

    BR Biopharma is a leading dividend payer. It pays a dividend yield of 4.27%, putting its dividend yield in the top 25% of dividend-paying stocks.

  • Dividend Growth

    BR Biopharma does not have a long track record of dividend growth.

  • Dividend Coverage

    The dividend payout ratio of BR Biopharma is 228.57%. Payout ratios above 75% are not desirable because they may not be sustainable.

  • Read more about BR Biopharma's dividend.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for BR Biopharma this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, BR Biopharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    29.35% of the stock of BR Biopharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    BR Biopharma has minimal institutional ownership at this time.

  • Read more about BR Biopharma's insider trading history.
Receive BRBI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BR Biopharma and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

BRBI Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

BRBI Stock Analysis - Frequently Asked Questions

BR Biopharma's stock was trading at $14.75 on February 17, 2026. Since then, BRBI shares have decreased by 49.8% and is now trading at $7.40.

BR Biopharma, Inc. (NASDAQ:BRBI) posted its quarterly earnings data on Tuesday, November, 3rd. The company reported $0.05 earnings per share (EPS) for the quarter. The firm earned $23.80 million during the quarter.
Read the conference call transcript
.

Shares of BRBI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

Record date for 9/4 Dividend
8/17/2026
Ex-Dividend for 9/4 Dividend
8/17/2026
Dividend Payable
9/04/2026
Last Earnings
11/03/2026
Record date for 12/4 Dividend
11/16/2026
Ex-Dividend for 12/4 Dividend
11/16/2026
Today
11/22/2026
Dividend Payable
12/04/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Finance
Industry
Capital Markets
Sub-Industry
Investment Banking & Brokerage
Current Symbol
NASDAQ:BRBI
CIK
2058601
Fax
N/A
Employees
189
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
N/A
Trailing P/E Ratio
52.86
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.90
Quick Ratio
0.90

Sales & Book Value

Annual Sales
$2.23 billion
Price / Sales
0.04
Cash Flow
$2.82 per share
Price / Cash Flow
2.62
Book Value
$13.70 per share
Price / Book
0.54

Miscellaneous

Outstanding Shares
11,810,000
Free Float
8,344,000
Market Cap
$87.39 million
Optionable
N/A
Beta
0.43
7 Energy Stocks to Buy and Hold Forever Cover

Oil still powers the global economy, but AI is reshaping the energy opportunity. Discover seven stocks spanning traditional energy, infrastructure, and next-generation power.

Get This Free Report

This page (NASDAQ:BRBI) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners